Developing a Risk Assessment Model for Thrombophilia in Females with Polycystic Ovary Syndrome PCOS Aged 14 to 45

What this Trial Is About

This observational case-control study focuses on females with polycystic ovary syndrome PCOS, a common hormonal disorder affecting reproductive-age women. The research aims to develop a comprehensive risk assessment model for abnormalities related to thrombophilia, specifically decreased protein C andor protein S levels. By analyzing endocrine, metabolic, and genetic factors, the study seeks to better understand risk factors associated with these clotting abnormalities in females with PCOS. Female participants aged 14 to 45 years diagnosed with PCOS will be included. Diagnosis for adults follows the 2023 international evidence-based guideline, requiring ovulatory dysfunction andor irregular menstrual cycles combined with clinical or biochemical hyperandrogenism or polycystic ovarian morphology. Adolescents must meet adolescent-specific diagnostic criteria requiring both ovulatory dysfunction or irregular cycles and hyperandrogenism. Participants are grouped based on the presence or absence of decreased protein C andor protein S levels for comparison. No treatments or interventions are administered as this is an observational study. Participants will provide data on endocrine, metabolic, and genetic variables for analysis. Researchers will perform various statistical analyses to evaluate the risk factors and develop the assessment model. The main outcome measured is the presence of decreased protein C andor protein S levels at baseline. The study involves assessments related to these measures and aims to inform individualized risk management for females with PCOS. The study is expected to complete by March 2027.

Construction of a Multi-dimensional Risk Assessment System: a Clinical Study of Polycystic Ovary Syndrome Complicated With Thrombophilia